Hypothesis

NAD+ depletion acts as a rheostat that lowers the activation threshold of the NLRP3 inflammasome in aged thymic myeloid cells, converting subthreshold damage signals into chronic inflammation. Restoring NAD+ raises this threshold, making inflammasome activation contingent on higher levels of mitochondrial ROS, lipotoxic molecules, or SASP factors.

Mechanistic Basis

• NAD+ is a cofactor for sirtuins (SIRT1‑3) and PARPs. In aging, falling NAD+ reduces SIRT2‑mediated deacetylation of NLRP3 and the adaptor ASC, promoting their acetylation‑driven oligomerization 1.
• Concurrently, accumulating DNA damage activates PARP1, which consumes NAD+ and further depresses sirtuin activity, creating a vicious loop that amplifies inflammasome sensitivity 2.
• Acetylated NLRP3 exhibits a lower threshold for activation by mitochondrial ROS and oxidized mtDNA, meaning that damage that would be innocuous in a NAD+‑rich environment now triggers IL‑1β release 3.

Testable Predictions

1. In thymic myeloid isolates from old mice, NAD+ boosting (e.g., nicotinamide riboside) will increase the amount of exogenous H2O2 or palmitate required to induce caspase‑1 cleavage and IL‑1β secretion by ≥2‑fold compared with untreated aged cells.
2. Conversely, acute NAD+ depletion via FK866 in young thymic myeloid cells will sensitize them to damage, lowering the effective EC50 for NLRP3 activation to levels observed in aged controls.
3. SIRT2 inhibition will phenocopy NAD+ loss, lowering the activation threshold even when NAD+ levels are high, confirming sirtuin mediation.

Experimental Design

• Isolate CD11b+ myeloid cells from thymuses of young (3 mo) and old (24 mo) mice.
• Treat cells with a titration of H2O2 (0‑500 µM) or palmitate‑BSA (0‑400 µM) in the presence or absence of NR (1 mM) or FK866 (10 nM).
• Measure caspase‑1 activity (FLICA assay) and secreted IL‑1β (ELISA) after 4 h.
• Determine EC50 values for each condition; compare across groups using two‑way ANOVA.
• Validate SIRT2 dependence by adding SIRT2‑specific agonist (AGK2) or siRNA knockdown.

Implications

If confirmed, this hypothesis reframes NAD+ decline not as a passive biomarker but as an active immunomodulatory switch that governs whether cellular damage translates into inflammasome‑driven immunosenescence. It suggests that NAD+ repletion strategies may need to be calibrated to damage load, and that combining NAD+ boosters with senolytics or mitochondrial antioxidants could synergistically raise the inflammasome threshold beyond the point of chronic activation.